Status: Not yet recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Participants needed: 180
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Ascentage Pharma Group Inc.Updated: Feb 20, 2026Locations: 2
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) status ≤ 1 in Part 1 (dose escalation)... [+4]
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immuno... [+16]